CONCORDBIO - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | CONCORDBIO | Market Cap | 11,533 Cr. | Current Price | 1,101 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 36.3 | Book Value | 174 ₹ | Dividend Yield | 0.97 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,218 ₹ | DMA 200 | 1,440 ₹ |
| Chg in FII Hold | -0.45 % | Chg in DII Hold | 0.03 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 38.4 | MACD | -20.4 | Volume | 65,770 | Avg Vol 1Wk | 2,42,338 |
| Low price | 1,057 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.35 | Debt to equity | 0.00 |
| 52w Index | 4.05 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 27.2 |
📊 Concord Biotech (CONCORDBIO) shows weak intraday potential today. RSI at 38.4 indicates oversold conditions but lacks strong reversal signals. MACD is negative (-20.4), confirming bearish sentiment. Current price (1,101 ₹) is below both 50 DMA (1,218 ₹) and 200 DMA (1,440 ₹), reflecting downward momentum. Volume (65,770) is significantly below average (2,42,338), limiting breakout chances.
💡 Optimal Buy Price: 1,080–1,090 ₹ (near support)
🎯 Profit-Taking Levels: 1,125–1,140 ₹ (short-term resistance)
🛑 Stop-Loss: 1,070 ₹ (recent low)
⏳ If already holding intraday: Exit near 1,125–1,130 ₹ if momentum weakens or if price fails to sustain above 1,100 ₹ with volume confirmation.
Positive
- Strong ROCE (28.4%) and ROE (21.4%) show efficient capital use.
- Debt-free balance sheet (Debt-to-equity: 0.00).
- EPS of 30.1 ₹ supports earnings stability.
Limitation
- Stock trading below both 50 DMA and 200 DMA indicates bearish trend.
- Quarterly profit variation (-5.20%) shows declining momentum.
- FII holdings decreased (-0.45%), reflecting reduced foreign investor confidence.
- Volume far below average, limiting intraday volatility opportunities.
Company Negative News
- No major negative news reported, but technical weakness and declining quarterly profit weigh on sentiment.
Company Positive News
- Quarterly PAT improved from 62.9 Cr. to 70.2 Cr., showing earnings growth despite margin pressures.
- Dividend yield of 0.97% provides shareholder returns.
Industry
- Industry P/E at 27.2 is lower than Concord Biotech’s 36.3, suggesting overvaluation relative to peers.
- Biotech sector remains growth-oriented but faces volatility due to regulatory and R&D risks.
Conclusion
⚠️ Concord Biotech is not an ideal intraday candidate today due to weak momentum, low volume, and price trading below key averages. Short-term traders may attempt a bounce trade near 1,080–1,090 ₹ with a tight stop-loss at 1,070 ₹, but risk remains elevated. Conservative traders should avoid aggressive intraday positions until momentum indicators improve.